Strand Life Sciences Expands Multi-Cancer Test Access, Aims for Cost Reduction
Strand Life Sciences plans to increase the availability of its CancerSpot test while reducing costs to ₹10,000.
Strand Life Sciences aims to make its CancerSpot test available in more hospitals.
The test currently costs ₹33,000, with plans to reduce it to ₹10,000.
The study shows a low false positive rate of 1.4% and can detect 70% of cancers.
Strand Life Sciences is set to broaden the reach of its innovative multi-cancer early detection test, CancerSpot, following a comprehensive four-year study conducted across 43 hospitals. The company's CEO, Dr. Ramesh Hariharan, announced that they are actively working to make this non-invasive blood test available in more healthcare facilities while aiming to significantly reduce its price to the ₹10,000 range from the current ₹33,000.
The CancerSpot test, which analyzes circulating tumor DNA in the blood, has been recognized for its effectiveness in early cancer detection. The findings from the study, published in the Proceedings of the National Academy of Sciences (PNAS), indicate that the test can identify cancers with a remarkably low false positive rate of approximately 1.4%, achieving a sensitivity rate where 70% of cancers can be detected. Dr. Hariharan emphasized the uniqueness of this study, noting that it is the first of its kind from India, although similar research has been conducted in the US and China.
One of the significant insights from the study is the synchronous increase in DNA from both tumor and immune cells in cancer patients, which challenges previous assumptions about cancer detection. The CancerSpot test utilizes advanced DNA sequencing and artificial intelligence to identify specific methylation patterns that differentiate cancer cells from healthy ones. Dr. Hariharan highlighted the importance of balancing sensitivity and minimizing false positives to ensure clinical utility and avoid unnecessary procedures.
Strand Life Sciences, a subsidiary of Reliance Industries, is positioning itself in a competitive landscape that includes established players like Guardant Health and Grail Inc., both of which have FDA-approved liquid biopsy tests. While these companies are expected to enter the Indian market with higher pricing, Dr. Hariharan claims that the data supporting CancerSpot's effectiveness is superior in certain aspects. The company is focused on expanding its presence in India and other regions, including Asia and Africa, where it sees significant potential for its testing solutions.
In addition to expanding CancerSpot's availability, Strand Life Sciences has recently partnered with AstraZeneca India to explore collaborative healthcare opportunities. This partnership aims to introduce cancer treatment selection tests to various state governments, with initial efforts already underway in Andhra Pradesh. The collaboration may eventually extend to broader screening initiatives, enhancing cancer detection and treatment options in the region.




